サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1285863

エクソソーム技術市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年

Exosome Technologies Market (Exosome Type: Loaded Cargos [Peptide, siRNA, mRNA, miRNA, Protein, Chemical, and Others] and Non-cargo) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 208 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
エクソソーム技術市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年
出版日: 2023年04月30日
発行: Transparency Market Research
ページ情報: 英文 208 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

エクソソーム技術市場- レポートの範囲

TMRの調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も掲載しています。

当レポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

当レポートは、世界市場における競合情勢を詳しく掘り下げています。世界市場で活動している主要企業を特定し、さまざまな属性の観点からプロファイルしています。当レポートで紹介されている市場企業の属性は、会社概要、財務状況、最近の動向、SWOTです。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • パイプライン分析
  • 技術の進歩
  • COVID-19感染症パンデミック別業界への影響（バリューチェーンと短期・中期・長期的な影響）

第6章 世界市場の分析と予測：エクソソームタイプ別

  • イントロダクションと定義
  • 主な調査結果と開発
  • エクソソームタイプ別の市場金額予測、2017～2031年
    • 搭載カーゴ
      • ペプチド
      • siRNA
      • mRNA
      • miRNA
      • タンパク質
      • 化学
      • その他
    • 非カーゴ
  • エクソソームタイプ別の市場の魅力

第7章 世界市場の分析と予測：細胞源別

  • イントロダクションと定義
  • 主な調査結果と開発
  • 細胞源別の市場金額予測、2017～2031年
    • HEK293細胞
    • MSC
    • 血小板
    • 赤血球
    • ナチュラルキラー細胞
    • その他
  • 細胞源別の市場の魅力

第8章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果と開発
  • 用途別の市場金額予測、2017～2031年
    • 治療学
      • 腫瘍学
      • 神経変性疾患
      • 心血管疾患
      • 感染症
      • 化粧品
    • 診断
  • 用途別の市場の魅力

第9章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果と開発
  • エンドユーザー別の市場金額予測、2017～2031年
    • 医療提供者
    • 製薬およびバイオテクノロジー企業
    • その他
  • エンドユーザー別の市場の魅力度

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 地域別の市場金額予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場魅力度

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

  • 市場企業-競合マトリックス（企業の階層および規模別）
  • 企業別市場シェア分析（2021）
  • 企業プロファイル
    • AEGLE Therapeutics
    • Aruna Bio, Inc.
    • Bio-Techne Corporation（Exosome Diagnostics, Inc.）
    • Carmine Therapeutics, Inc.
    • Codiak BioSciences, Inc.
    • Creative Biolabs
    • Danaher Corporation（Beckman Coulter, Inc.）
    • Fujifilm Holdings Corporation
    • NOVADIP Biosciences SA
    • OmniSpirant Limited
    • Thermo Fisher Scientific, Inc.
図表

List of Tables

  • Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
  • Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
  • Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 08: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
  • Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
  • Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
  • Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
  • Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 22: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
  • Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
  • Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 29: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
  • Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
  • Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 36: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031
  • Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031
  • Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
  • Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
  • Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
  • Figure 03: Global Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
  • Figure 04: Global Exosome Technologies Market (US$ Mn), by Loaded Cargos, 2017-2031
  • Figure 05: Global Exosome Technologies Market (US$ Mn), by Non-cargo, 2017-2031
  • Figure 06: Global Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 07: Global Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 08: Global Exosome Technologies Market (US$ Mn), by HEK293 Cells, 2017-2031
  • Figure 09 Global Exosome Technologies Market (US$ Mn), by MSCs, 2017-2031
  • Figure 10: Global Exosome Technologies Market (US$ Mn), by Platelets, 2017-2031
  • Figure 11: Global Exosome Technologies Market (US$ Mn), by Erythrocytes, 2017-2031
  • Figure 12: Global Exosome Technologies Market (US$ Mn), by Natural Killer Cells, 2017-2031
  • Figure 13: Global Exosome Technologies Market (US$ Mn), by Others, 2017-2031
  • Figure 14: Global Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 15: Global Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 16: Global Exosome Technologies Market (US$ Mn), by Therapeutics, 2017-2031
  • Figure 17: Global Exosome Technologies Market (US$ Mn), by Diagnostics, 2017-2031
  • Figure 18: Global Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 19: Global Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 20: Global Exosome Technologies Market (US$ Mn), by Health Care Providers, 2017-2031
  • Figure 21: Global Exosome Technologies Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 22: Global Exosome Technologies Market (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Exosome Technologies Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 24: Global Exosome Technologies Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 25: North America Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 26: North America Exosome Technologies Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 27: North America Exosome Technologies Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 28: North America Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
  • Figure 29: North America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
  • Figure 30: North America Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 31: North America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 32: North America Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 33: North America Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 34: North America Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 35: North America Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 36: Europe Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 38: Europe Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 39: Europe Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
  • Figure 40: Europe Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
  • Figure 41: Europe Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 42: Europe Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 43: Europe Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 44: Europe Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 45: Europe Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 46: Europe Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 47: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 48: Asia Pacific Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 49: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 50: Asia Pacific Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
  • Figure 51: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
  • Figure 52: Asia Pacific Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 53: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 54: Asia Pacific Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 55: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 56: Asia Pacific Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 57: Asia Pacific Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 58: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 59: Latin America Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 60: Latin America Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 61: Latin America Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
  • Figure 62: Latin America Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
  • Figure 63: Latin America Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 64: Latin America Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 65: Latin America Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 66: Latin America Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 67: Latin America Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 68: Latin America Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 69: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 70: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 71: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 72: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Exosome Type, 2022 and 2031
  • Figure 73: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Exosome Type, 2023-2031
  • Figure 74: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Cell Source, 2022 and 2031
  • Figure 75: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Cell Source, 2023-2031
  • Figure 76: Middle East & Africa Exosome Technologies Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 77: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 78: Middle East & Africa Exosome Technologies Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 79: Middle East & Africa Exosome Technologies Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 80: Global Exosome Technologies Market Share Analysis, by Company, 2022
目次
Product Code: TMRGL65840

Exosome Technologies Market - Scope of Report

TMR's report on the global Exosome Technologies Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Exosome Technologies Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Exosome Technologies Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Exosome Technologies market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Exosome Technologies market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Exosome Technologies market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Exosome Technologies market.

The report delves into the competitive landscape of the global Exosome Technologies market. Key players operating in the global Exosome Technologies Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Exosome Technologies Market profiled in this report.

Key Questions Answered in Global Exosome Technologies Market Report:

  • What is the sales/revenue generated by Exosome Technologies across all regions during the forecast period?
  • What are the opportunities in the global Exosome Technologies market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Exosome Technologies Market - Research Objectives and Research Approach

The comprehensive report on the global Exosome Technologies Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Exosome Technologies Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Exosome Technologies market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Exosome Technologies Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Exosome Type Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Exosome Technologies Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Technological Advancements
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Exosome Technologies Market Analysis and Forecasts, by Exosome Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Exosome Type, 2017 - 2031
    • 6.3.1. Loaded Cargos
      • 6.3.1.1. Peptide
      • 6.3.1.2. siRNA
      • 6.3.1.3. mRNA
      • 6.3.1.4. miRNA
      • 6.3.1.5. Protein
      • 6.3.1.6. Chemical
      • 6.3.1.7. Others
    • 6.3.2. Non-cargo
  • 6.4. Market Attractiveness By Exosome Type

7. Global Exosome Technologies Market Analysis and Forecasts, by Cell Source

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Cell Source, 2017 - 2031
    • 7.3.1. HEK293 Cells
    • 7.3.2. MSCs
    • 7.3.3. Platelets
    • 7.3.4. Erythrocytes
    • 7.3.5. Natural Killer Cells
    • 7.3.6. Others
  • 7.4. Market Attractiveness By Cell Source

8. Global Exosome Technologies Market Analysis and Forecasts, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Application, 2017 - 2031
    • 8.3.1. Therapeutics
      • 8.3.1.1. Oncology
      • 8.3.1.2. Neurodegenerative Diseases
      • 8.3.1.3. Cardiovascular Diseases
      • 8.3.1.4. Infectious Diseases
      • 8.3.1.5. Cosmetics
    • 8.3.2. Diagnostics
  • 8.4. Market Attractiveness By Application

9. Global Exosome Technologies Market Analysis and Forecasts, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2017 - 2031
    • 9.3.1. Health Care Providers
    • 9.3.2. Pharmaceutical & Biotechnology Companies
    • 9.3.3. Others
  • 9.4. Market Attractiveness By End-user

10. Global Exosome Technologies Market Analysis and Forecasts, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Exosome Technologies Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Exosome Type, 2017 - 2031
    • 11.2.1. Loaded Cargos
      • 11.2.1.1. Peptide
      • 11.2.1.2. siRNA
      • 11.2.1.3. mRNA
      • 11.2.1.4. miRNA
      • 11.2.1.5. Protein
      • 11.2.1.6. Chemical
      • 11.2.1.7. Others
    • 11.2.2. Non-cargo
  • 11.3. Market Value Forecast By Cell Source, 2017 - 2031
    • 11.3.1. HEK293 Cells
    • 11.3.2. MSCs
    • 11.3.3. Platelets
    • 11.3.4. Erythrocytes
    • 11.3.5. Natural Killer Cells
    • 11.3.6. Others
  • 11.4. Market Value Forecast By Application, 2017 - 2031
    • 11.4.1. Therapeutics
      • 11.4.1.1. Oncology
      • 11.4.1.2. Neurodegenerative Diseases
      • 11.4.1.3. Cardiovascular Diseases
      • 11.4.1.4. Infectious Diseases
      • 11.4.1.5. Cosmetics
    • 11.4.2. Diagnostics
  • 11.5. Market Value Forecast By End-user, 2017 - 2031
    • 11.5.1. Health Care Providers
    • 11.5.2. Pharmaceutical & Biotechnology Companies
    • 11.5.3. Others
  • 11.6. Market Value Forecast By Country, 2017 - 2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Exosome Type
    • 11.7.2. By Cell Source
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Exosome Technologies Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Exosome Type, 2017 - 2031
    • 12.2.1. Loaded Cargos
      • 12.2.1.1. Peptide
      • 12.2.1.2. siRNA
      • 12.2.1.3. mRNA
      • 12.2.1.4. miRNA
      • 12.2.1.5. Protein
      • 12.2.1.6. Chemical
      • 12.2.1.7. Others
    • 12.2.2. Non-cargo
  • 12.3. Market Value Forecast By Cell Source, 2017 - 2031
    • 12.3.1. HEK293 Cells
    • 12.3.2. MSCs
    • 12.3.3. Platelets
    • 12.3.4. Erythrocytes
    • 12.3.5. Natural Killer Cells
    • 12.3.6. Others
  • 12.4. Market Value Forecast By Application, 2017 - 2031
    • 12.4.1. Therapeutics
      • 12.4.1.1. Oncology
      • 12.4.1.2. Neurodegenerative Diseases
      • 12.4.1.3. Cardiovascular Diseases
      • 12.4.1.4. Infectious Diseases
      • 12.4.1.5. Cosmetics
    • 12.4.2. Diagnostics
  • 12.5. Market Value Forecast By End-user, 2017 - 2031
    • 12.5.1. Health Care Providers
    • 12.5.2. Pharmaceutical & Biotechnology Companies
    • 12.5.3. Others
  • 12.6. Market Value Forecast By Country, 2017 - 2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Exosome Type
    • 12.7.2. By Cell Source
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country

13. Asia Pacific Exosome Technologies Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Exosome Type, 2017 - 2031
    • 13.2.1. Loaded Cargos
      • 13.2.1.1. Peptide
      • 13.2.1.2. siRNA
      • 13.2.1.3. mRNA
      • 13.2.1.4. miRNA
      • 13.2.1.5. Protein
      • 13.2.1.6. Chemical
      • 13.2.1.7. Others
    • 13.2.2. Non-cargo
  • 13.3. Market Value Forecast By Cell Source, 2017 - 2031
    • 13.3.1. HEK293 Cells
    • 13.3.2. MSCs
    • 13.3.3. Platelets
    • 13.3.4. Erythrocytes
    • 13.3.5. Natural Killer Cells
    • 13.3.6. Others
  • 13.4. Market Value Forecast By Application, 2017 - 2031
    • 13.4.1. Therapeutics
      • 13.4.1.1. Oncology
      • 13.4.1.2. Neurodegenerative Diseases
      • 13.4.1.3. Cardiovascular Diseases
      • 13.4.1.4. Infectious Diseases
      • 13.4.1.5. Cosmetics
    • 13.4.2. Diagnostics
  • 13.5. Market Value Forecast By End-user, 2017 - 2031
    • 13.5.1. Health Care Providers
    • 13.5.2. Pharmaceutical & Biotechnology Companies
    • 13.5.3. Others
  • 13.6. Market Value Forecast By Country, 2017 - 2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Exosome Type
    • 13.7.2. By Cell Source
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country

14. Latin America Exosome Technologies Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Exosome Type, 2017 - 2031
    • 14.2.1. Loaded Cargos
      • 14.2.1.1. Peptide
      • 14.2.1.2. siRNA
      • 14.2.1.3. mRNA
      • 14.2.1.4. miRNA
      • 14.2.1.5. Protein
      • 14.2.1.6. Chemical
      • 14.2.1.7. Others
    • 14.2.2. Non-cargo
  • 14.3. Market Value Forecast By Cell Source, 2017 - 2031
    • 14.3.1. HEK293 Cells
    • 14.3.2. MSCs
    • 14.3.3. Platelets
    • 14.3.4. Erythrocytes
    • 14.3.5. Natural Killer Cells
    • 14.3.6. Others
  • 14.4. Market Value Forecast By Application, 2017 - 2031
    • 14.4.1. Therapeutics
      • 14.4.1.1. Oncology
      • 14.4.1.2. Neurodegenerative Diseases
      • 14.4.1.3. Cardiovascular Diseases
      • 14.4.1.4. Infectious Diseases
      • 14.4.1.5. Cosmetics
    • 14.4.2. Diagnostics
  • 14.5. Market Value Forecast By End-user, 2017 - 2031
    • 14.5.1. Health Care Providers
    • 14.5.2. Pharmaceutical & Biotechnology Companies
    • 14.5.3. Others
  • 14.6. Market Value Forecast By Country, 2017 - 2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Exosome Type
    • 14.7.2. By Cell Source
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country

15. Middle East & Africa Exosome Technologies Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Exosome Type, 2017 - 2031
    • 15.2.1. Loaded Cargos
      • 15.2.1.1. Peptide
      • 15.2.1.2. siRNA
      • 15.2.1.3. mRNA
      • 15.2.1.4. miRNA
      • 15.2.1.5. Protein
      • 15.2.1.6. Chemical
      • 15.2.1.7. Others
    • 15.2.2. Non-cargo
  • 15.3. Market Value Forecast By Cell Source, 2017 - 2031
    • 15.3.1. HEK293 Cells
    • 15.3.2. MSCs
    • 15.3.3. Platelets
    • 15.3.4. Erythrocytes
    • 15.3.5. Natural Killer Cells
    • 15.3.6. Others
  • 15.4. Market Value Forecast By Application, 2017 - 2031
    • 15.4.1. Therapeutics
      • 15.4.1.1. Oncology
      • 15.4.1.2. Neurodegenerative Diseases
      • 15.4.1.3. Cardiovascular Diseases
      • 15.4.1.4. Infectious Diseases
      • 15.4.1.5. Cosmetics
    • 15.4.2. Diagnostics
  • 15.5. Market Value Forecast By End-user, 2017 - 2031
    • 15.5.1. Health Care Providers
    • 15.5.2. Pharmaceutical & Biotechnology Companies
    • 15.5.3. Others
  • 15.6. Market Value Forecast By Country, 2017 - 2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Exosome Type
    • 15.7.2. By Cell Source
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2021)
  • 16.3. Company Profiles
    • 16.3.1. AEGLE Therapeutics
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Test Type Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Aruna Bio, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Test Type Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bio-Techne Corporation (Exosome Diagnostics, Inc.)
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Test Type Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Carmine Therapeutics, Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Test Type Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Codiak BioSciences, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Test Type Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Creative Biolabs
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Test Type Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Danaher Corporation (Beckman Coulter, Inc.)
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Test Type Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Fujifilm Holdings Corporation
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Test Type Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. NOVADIP Biosciences S.A.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Test Type Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. OmniSpirant Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Test Type Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Thermo Fisher Scientific, Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Test Type Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview